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Abstract
Background: Mutations in the genes encoding leptin (LEP), the leptin receptor (LEPR), and the melanocortin 4
receptor (MC4R) are known to cause severe early-onset childhood obesity. The aim of the current study was to
examine the prevalence of damaging LEP, LEPR, and MC4R mutations in Pakistani families having a recessive
heritance of early-onset obesity.
Methods: Using targeted resequencing, the presence of rare mutations in LEP, LEPR, and MC4R, was investigated in
individuals from 25 families suspected of having autosomal recessive early-onset obesity. Segregation patterns of
variants were assessed based on chip-based genotyping.
Results: Homozygous LEPR variants were identified in two probands. One carried a deletion (c.3260AG) resulting in
the frameshift mutation p.Ser1090Trpfs*6, and the second carried a substitution (c.2675C > G) resulting in the
missense mutation p.Pro892Arg. Both mutations were located within regions of homozygosity shared only among
affected individuals. Both probands displayed early-onset obesity, hyperphagia and diabetes. No mutations were
found in LEP and MC4R.
Conclusions: The current study highlights the implication of LEPR mutations in cases of severe early-onset obesity
in consanguineous Pakistani families. Through targeted resequencing, we identified novel damaging mutations, and
our approach may therefore be utilized in clinical testing or diagnosis of known forms of monogenic obesity with
the aim of optimizing obesity treatment.
Keywords: Early-onset obesity, Hyperphagia, Leptin, Leptin receptor, Melanocortin 4 receptor, Monogenic obesity,
Pakistani families, Targeted resequencing
Background
Currently, childhood obesity is considered one of the
most serious public health challenges of the twenty-first
century. The prevalence of childhood obesity is increas-
ing at an alarming rate, affecting high-income as well as
low- and middle-income countries, and the number of
overweight and obese children below the age of five is
estimated to be 41 million [http://www.who.int/topics/
obesity/en.].
A strong genetic factor is evident in the etiology of
obesity, with heritability estimates ranging from 40 to
70% [1–3]. Genetic defects disrupting the leptin-mela-
nocortin signaling pathway very often result in severe
early-onset obesity and hyperphagia [4–6], and the
genes most commonly involved in monogenic forms
of obesity are part of this pathway, including leptin
(LEP), the leptin receptor (LEPR), and the melanocor-
tin 4 receptor (MC4R) [7–9]. Leptin is a 16-KD hor-
mone secreted by white adipocytes which binds to
LEPR and regulates energy expenditure through hypo-
thalamic neurons [10]. LEPR is a member of the cyto-
kine receptor family with six isoforms (LEPRa-f ), yet,
leptin signaling is primarily mediated by the long
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LEPRb expressed in the hypothalamus [11–13]. The
short form is expressed in a number of tissues, in-
cluding the adrenal gland, kidney, lung, and choroid
plexus [14, 15]. The mutations identified to date in
LEP and LEPR are ethnic-specific, and the prevalence
of monogenic obesity caused by mutations within
these two genes is as high as > 20% in Pakistani study
populations with obesity [16–18].
MC4R encodes a 332- amino acid membrane-bound
receptor protein [19]. It is expressed in the brain and it
influences appetite regulation through interaction with
adrenocorticotropic and melanocyte stimulating hor-
mones (MSH) through G proteins [20]. In studies of
European populations with severe obesity, the preva-
lence of heterozygous damaging MC4R mutations is
~ 6% and ~ 2% in children and adults, respectively
[21–23], signifying the different etiologies of child-
hood and adult obesity.
The disruption of LEPR and leptin deficiency results
in severe early-onset hyperphagic obesity with rapid
weight increase during the first few months of life
[17, 24, 25]. Similarly, during the first year of life,
MC4R deficiency has been linked with hyperphagia
and increased fat and lean mass, increased linear
height, increased bone mineral density and severe
early hyperinsulinemia [22, 26], although some of
these associations remain controversial [27, 28]. Obes-
ity caused by damaging mutations in LEP and LEPR
display an autosomal recessive mode of inheritance
while obesity caused by MC4R mutations exhibit vari-
able penetrance (recessive or co-dominant) [23].
Genetic sequencing of consanguineous families is an
important tool in the identification of deleterious muta-
tions in genes implicated in monogenic forms of obesity
[18], as consanguineous families share homozygous
regions in their genomes, enabling the identification of
deleterious recessive mutations [29]. Due to the high
degree of inbreeding in the Pakistani population, homo-
zygous deleterious mutations in LEP, LEPR, and MC4R
have been identified in as many as ~ 30% of severely
obese individuals from consanguineous families [16–18].
In comparison, the prevalence of heterozygous MC4R
mutations is 3–5% in Caucasian populations with
early-onset obesity [30, 31]. Both LEP and LEPR muta-
tions are rare in Caucasian populations.
The application of next generation sequencing
(NGS) provides a powerful method to discover rare
disease-causing genetic variants [32]. Therefore, tar-
geted resequencing of LEP, LEPR and MC4R was per-
formed to assess the prevalence of damaging
mutations within these genes. In total, genetic screen-
ing was performed in 25 severely obese probands
from Pakistani families of which 14 probands were
from families with known consanguineous marriages.
Methods
Study design
This family-based study applied a phenotype-driven ap-
proach to investigate monogenic causes of obesity in se-
lected Pakistani families with obesity segregating in an
autosomal recessive pattern.
Participants
Twenty-five families, originating from different regions
of Pakistan, were recruited and examined at Children
Hospital, Pakistan Institute of Medical Sciences (PIMS),
Islamabad. Consanguineous marriages were known in 14
of the included families. The selection of the families
was based on three criteria: 1) Body mass index (BMI)
of probands > 30 kg/m2; 2) Probands displaying obesity
onset before five years of age; and 3) Parents of the pro-
bands with BMI < 25 kg/m2, consistent with an auto-
somal recessive mode of inheritance.
Clinical examination
Through interview sessions, information on age of obes-
ity onset (years), other major chronic disease(s) (if any),
metabolic disorder(s) running in the family, eating
habits, physical activity, along with obesity-related
co-morbidities was recorded. Waist circumference (cm)
and height (cm) were measured with a non-elastic plas-
tic tape with the participant standing in an upright pos-
ition without shoes. Weight (kg), without shoes and in
light clothes, was measured to the nearest 0.1 kg using a
digital scale. From these measures, BMI was calculated
as the weight in kilograms divided by the square of the
height in meters (kg/m2), and using the LMS method
[33], a BMI standard deviation score (SDS) was calcu-
lated based on a World Health Organization (WHO) ref-
erence population [34]. Approximately 3–5 ml of venous
non-fasting blood from affected and un-affected family
members were collected in 8.5 ml vacutainer tubes (BD
Vacutainer® ACD, Franklin Lakes NJ, USA). Clinical
characteristics of the families are presented in
Additional file 1.
Genomic DNA extraction
DNA was extracted from blood samples from 36 affected
and 88 unaffected family members. Genomic DNA was
primarily extracted using the standard phenol-chloroform
method [35], however, in some families, the QIAamp
DNA Mini Kit (Qiagen, Germany) was used.
Targeted resequencing
The probands (n = 25) from each family as well as four
additional affected individuals (OB2–6, OB4–8, OB4–9,
and OB4–10) underwent targeted resequencing. Using a
chip-based customized nucleotide probe, targeted rese-
quencing was performed to examine the coding regions
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of LEP, LEPR, and MC4R. Methods for target region cap-
ture and NGS have previously been extensively described
[36]. According to the manufacturer’s standard cluster
generation and sequencing protocols, the final captured
DNA libraries were sequenced using the Illumina
HiSeq2000 Analyzers as PE 90 bp reads. Only variants
having a minimum mean depth of 20x were included.
Identified variants were annotated according to the tran-
scripts 1) LEP: NM_000230; 2) LEPR: NM_002303.5 and
3) MC4R: NM_005912.
Chip genotyping
Illumina Infinium Human CoreExome Bead Chip (Cor-
eExomeChip) genotyping was performed in 124 individ-
uals from 25 families using Illumina’s HiScan system at
the laboratory facilities of the Novo Nordisk Foundation
Center for Basic Metabolic Research at Symbion,
Copenhagen, Denmark. The standard pipeline in Illu-
mina Genome Studio software was used for the geno-
type calling. The pipeline yielded 551,839 genetic
variations, which entered our quality control (QC) pipe-
line. The Illumina final report was converted to plink
format using custom scripts and aligned with the posi-
tive strand of the GRCh37 reference.
QC included removal of variants with missing geno-
types above 5% as well as individuals with more than 5%
missing genotype calls, individuals with negative in-
breeding, indication of duplicated samples, and discrep-
ancy between genetic identified pedigree and the
pedigree obtained from the family. A total of 12 individ-
uals were removed in the QC. We did not remove SNPs
deviating from Hardy-Weinberg equilibrium as is other-
wise usual, since these variants may be of interest given
the specific mode of data sampling.
Homozygosity mapping
Based on genotyping, runs of homozygosity were deter-
mined in each family using the “homozyg” command in
PLINK [37].
Results
In the present study, targeted resequencing data was com-
bined with chip-based genotyping, enabling the identifica-
tion of rare and potentially novel causal variants
co-segregating with obesity. No coding variants were identi-
fied within MC4R and LEP. However, in LEPR eight coding
variants were identified, of which two were synonymous,
five were missense and one was a frame-shift mutation.
Identified mutations were classified as potentially dam-
aging, if they were: 1) non-synonymous; 2) rare in the gen-
eral population with a minor allele frequency below 0.1%
[38, 39] and 3) homozygous or if two or more heterozygous
mutation were present within the same gene. Two identi-
fied variants fulfilled these criteria; one was a frame-shift
variant (p.Ser1090Trpfs*6) and the other was a missense
mutation (p.Pro892Arg). The pathogenicity of the missense
variant was assessed using CADD scores [40].
Frameshift mutation (Ser1090Trpfs*6)
In family OB4, the novel homozygous frameshift muta-
tion c.3260AG (p.Ser1090Trpfs*6) which truncates the
LEPR protein, was identified in exon 20 of the LEPR
(Fig. 1). This frameshift was the result of a deletion of
AG at nucleotide position 66,102,459 to 66,102,461. This
mutation was located within the homozygosity region on
chromosome 1p31.1 from position 55,397,406 to
75,241,971. This homozygous region was only shared
among affected family members.
Affected members in the family OB4, originating from
the Rajanpur district of the Punjab province in Pakistan,
had a very homogenous phenotype, comprising hyper-
phagia and rapid weight gain resulting in morbid obesity
at an early age. This severe phenotype was evident in
several affected family members, including two females
(OB4–7 and OB4–8) aged 12 and 8 years, respectively,
as well as two male first cousins (OB4–9 and OB4–10)
aged 10 and 8 years, respectively. At the time of recruit-
ment of the family, the proband OB4–7, aged 12 years,
weighed 145.0 kg with a BMI SDS of 4.48 and BMI of
62.8 kg/m2 (Table 1). At follow-up, the proband was
14 years old with pubertal stage of Tanner IV [41], yet,
without menarche and had developed diabetes with
C-peptide level of 0.92 nmol/L. Moreover, the sibling
(OB4–8) and two affected cousins (OB4–9, OB4–10)
were in the pubertal stage of Tanner I [41, 42]. The se-
verity of the mutation was evaluated based on the sex of
the carriers, as a sex-specific effect of LEPR mutations
has previously been suggested [43]. However, we did not
find any effect of the mutation influenced by the sex of
the carriers (Table 2).
Missense mutation (p.Pro892Arg)
The novel missense mutation p.Pro892Arg, located in
exon 20 in LEPR, was identified in proband OB25–4 of
family OB25 (Fig. 2). This mutation was located at pos-
ition 66,101,875 within a homozygous region from pos-
ition 59,653,630 to 91,206,170 on chromosome 1p31.
Born of a consanguineous marriage, the proband pre-
sented with a normal birth weight of 3.0 kg but after
two months, she rapidly gained weight and attained the
weight of 18.0 kg at the age of one year, corresponding
to a BMI SDS of 6.49 (Table 1). In addition, the proband
suffered from diabetes and displayed developmental
delay. The proband was also in the pubertal stage of
Tanner I. When annotated using online bioinformatics
tools, p.Pro892Arg was predicted to be damaging and
had CADD score of 28, strongly suggesting the mutation
to be deleterious.
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Discussion
In the present study, we employed targeted resequencing
as a means to identify the genetic etiology in cases with
severe early-onset obesity. The sequencing data was ana-
lyzed with respect to the three main genes known to be
involved in monogenic forms of obesity, i.e. LEP, LEPR
and MC4R. Given the high prevalence of LEP, LEPR and
MC4R mutations previously reported in Pakistani popu-
lations [18], a similarly high prevalence of causal variants
within these genes was expected. However, only two of
the 25 examined probands carried homozygous recessive
mutations, and both mutations were positioned in LEPR.
LEPR mutations have previously been reported to in-
fluence the risk of developing severe early-onset obesity,
hypogonadotropic hypogonadism and hypothalamic
hypothyroidism [24, 44], which is similar to the clinical
characteristics of leptin deficiency [24]. Furthermore, in
mice, Lepr mutations have been found to influence the
susceptibility of type 2 diabetes [45]. Hypogonadotropic
hypogonadism in LEPR-deficient individuals may be due
to a defect both at the hypothalamic and the pituitary
level [46]. However, hypogonadism may change over
time, as in the case of spontaneous pubertal develop-
ment and a natural pregnancy [24].
Table 1 Clinical characteristics of probands with homozygous LEPR mutations
Proband OB4–7 Proband OB25–4
Family ID OB4 OB25
Sex Female Female
Age at enrolment (years) 12.18 1.03
Age at obesity onset 40 days 60 days
Height (cm) 152.0 76.2
Weight (kg) 145.0 18.0
BMI (kg/m2) 62.8 31.0
BMI SDS 4.49 6.49
Waist circumference (cm) 137.0 73.6
Family history of obesity No No
Related co-morbidities Diabetes Diabetes, dyslipidaemia, hepatic and renal function disorder
Mutation type Frameshift Missense
Fig. 1 Pedigree of family OB4 with the frameshift mutation c.3260AG (p.Ser1090Trpfs*6) in LEPR
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Both of the novel LEPR mutations identified in the
current study, are positioned in the intracellular domain
of LepRb, which is involved in energy homeostasis,
glucose metabolism, fertility, growth and the action of
insulin [47, 48] . Upon binding, leptin activates the
LepRb through the mediation of multiple signaling
pathways, including phosphorylation of cytoplasmic
tyrosine kinases of Janus Kinase 2 (JAK2), conscription
of signal transducer and activator of transcription 3
(STAT3) and mitogen-activated protein kinase (MAPK)
cascade [47, 49–51]. In both humans and mice, multiple
forms of LepRb are known, including short intracellular
domain forms ranging from 32 to 40 amino acids and the
long form comprising 303 amino acids, which is predom-
inantly expressed in the hypothalamus [14, 48, 52–54].
The missense mutation (p.Pro892Arg), identified in a fam-
ily OB25, is located in the Box 1 motif which is important
both for leptin-dependent JAK2 activation through the
mediation of signaling by the intracellular domain and for
Table 2 Sex stratified analysis of BMI, weight and waist of
homozygous carriers of the LEPR p.Ser1090Trpfs*6 mutation in
family OB4
BMI (kg/m2) BMI SDS Weight (kg) Waist (cm)
Female carriers
OB4–7 62.8 4.49 145.0 137.0
OB4–8 38.2 4.40 75.0 111.7
Mean (SD) 50.5 (17.4) 4.44 (0.062) 110.0 (49.5) 124.4 (17.9)
Male carriers
OB4–9 40.8 4.18 80.2 111.7
OB4–10 41.0 5.39 55.0 99.0
Mean (SD) 40.9 (0.15) 4.79 (0.85) 67.6 (17.8) 105.4 (8.98)
p-value* 0.6 0.7 0.4 0.3
*Evaluated using a t-test
Fig. 2 Pedigree of family OB25 with the missense mutation c.2675C > G (p.Pro892Arg) in LEPR
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the physiologic actions of leptin [52, 55]. The CADD score
of the identified mutation (p.Pro892Arg) is 28, which indi-
cates this is a very likely disease-causing variant. The sec-
ond mutation, i.e. frameshift (Ser1090Trpfs*6) identified in
the family OB4, is located in the long intracellular domain
of LepRb and has sequence motifs resulting in the trunca-
tion of the domain, thereby suggesting a dysfunctional ef-
fect on its intracellular signal-transducing capabilities.
The highly deleterious nature of the identified two
mutations (p.Pro892Arg and Ser1090Trpfs*6) is consist-
ent with the clinical conditions of hyperphagia, rapid
weight gain and extreme obesity observed in proband
OB4–7. In both probands, the mutations were found in
a homozygous state, and based on genotyping of family
members, the homozygous region was found to be
shared among affected individuals only, while parents of
the probands were heterozygous carriers. Thus, when
combined, our results strongly indicate that the identi-
fied mutations are causal.
Previously, it has been observed that boys in the Paki-
stani population are more prone to obesity than girls
[56]. In addition, Iranian consanguineous families have
revealed that LEPR deficiency may be more severe in fe-
males compared to males [43]. However, in OB4 where
the mutation was found in both affected boys and girls,
it showed the same level of severity irrespective of sex.
Increasing knowledge of genetic factors involved in the
development of childhood obesity leads towards an
improved understanding of the genetic etiology of this
disorder. For this purpose the Pakistani population is
unique due to its large size, its high number of families
with known consanguineous marriages and the high
frequency of large pedigrees [56]. Especially the identifi-
cation of rare, damaging variants predisposing to obesity
holds promise to the future development of novel thera-
peutic options and personalized medicine based on
molecular diagnosis [24, 57]. In the case of congenital
leptin deficiency caused by deleterious LEP mutations,
hormonal leptin therapy has proved to have dramatic
treatment effects, successfully decreasing the body
weight and hyperphagia of the carriers [58, 59]. Recently,
treatment with mechanism-based therapy using a MC4R
agonist (setmelanotide) in two patients with damaging
pro-opiomelanocortin (POMC) mutations completely re-
versed hyperphagia and induced a remarkable weight
loss while normalizing insulin sensitivity [60]. Albeit no
effective drug therapies are currently available for LEPR
deficient individuals, treatment of dysfunctional POMC
with MC4R-agonist suggests its efficacy in other mono-
genic defects of the hypothalamic leptin-melanocortin
pathway, including LEPR deficient patients [60]. Hence,
the treatment with setmelanotide might be an effective
in treatment of probands with non-functional LEPR, as
identified in our study.
Yet, within 23 of the probands included in the present
study, no causal variants were identified. For these
remaining probands, the application of whole exome se-
quencing may be an important means to examine
whether damaging mutations in other, yet unknown
genes, may be the cause of their inherited early-onset
obesity.
Conclusion
Using targeted resequencing in consanguineous Paki-
stani families, two novel mutations, including a frame-
shift and a missense mutation, were identified in
probands with severe early-onset obesity. Both of these
mutations were identified in a homozygous state. Our
findings demonstrate the effectiveness of targeted rese-
quencing to identify rare coding pathogenic mutations
in consanguineous cases of severe early-onset obesity.
Additional file
Additional file 1: Clinical characteristics of 34 affected individuals in 25
families. (DOCX 33 kb)
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